Kernan N A, Flomenberg N, Dupont B, O'Reilly R J
Transplantation. 1987 Jun;43(6):842-7.
Clinical trials with bone marrow depleted of donor T lymphocytes indicate that both the incidence and severity of graft-versus-host disease (GVHD) in patients undergoing bone marrow transplantation (BMT) for treatment of leukemia are greatly reduced. However, there has been a concurrent increase in the incidence of graft rejection, particularly among recipients of HLA-nonidentical marrow grafts. In order to investigate the nature of graft failure, peripheral blood mononuclear cells (PBMC) present at the time of graft failure have been characterized by phenotypic and functional analyses in 5 recipients of HLA-nonidentical marrow grafts. Rejection of HLA-nonidentical marrow grafts was associated with the emergence of host-derived T lymphocytes in all 5 patients. In 3 of these patients, the cells could be tested directly for cell-mediated cytotoxicity. Antidonor cytotoxicity was detected in each of these 3 patients. In one patient the target specificity of the cytotoxic lymphocytes was identified as the donor class I HLA antigen, HLA-B7. None of the patient PBMC mediated cytotoxicity against the natural killer cell target K562.
对去除供体T淋巴细胞的骨髓进行的临床试验表明,接受骨髓移植(BMT)治疗白血病的患者中,移植物抗宿主病(GVHD)的发生率和严重程度均大幅降低。然而,移植排斥反应的发生率同时有所增加,尤其是在接受HLA不匹配骨髓移植的受者中。为了研究移植失败的本质,对5名接受HLA不匹配骨髓移植的受者在移植失败时的外周血单个核细胞(PBMC)进行了表型和功能分析。在所有5名患者中,HLA不匹配骨髓移植的排斥反应与宿主来源的T淋巴细胞出现有关。在其中3名患者中,可以直接检测细胞介导的细胞毒性。在这3名患者中均检测到抗供体细胞毒性。在1名患者中,细胞毒性淋巴细胞的靶标特异性被确定为供体I类HLA抗原HLA-B7。没有患者的PBMC对自然杀伤细胞靶标K562介导细胞毒性。